Board of Directors

Michael Spellacy joined Enfusion’s Board of Directors as Chair of the Board in early 2023. Spellacy currently serves as Chief Executive Officer and Director of Atlas Crest Investment Corp., Spellacy has extensive experience in technology, data and analytics, capital markets and private equity, and has worked as an investor, investment banker and consultant. Most recently, Spellacy was a Senior Managing Director at Accenture and Global Industry Leader of Accenture Capital Markets while overseeing Accenture’s Asset Management, Wealth Management and Investment and Trading businesses. Prior to Accenture, Spellacy was a Senior Partner, Asset and Wealth Management, at PricewaterhouseCoopers from 2015 to 2017.

Spellacy received his B.S. in Economics from the London School of Economics and MBA from the University of Hartford.

Brad Bernstein is Managing Partner of FTV Capital, a sector-focused growth equity investment firm. He has over 30 years of private equity experience.

Prior to FTV Capital, Bernstein was a partner at Oak Hill Capital Management and its predecessors, where he managed the business and financial services group. He held roles at Patricof & Company Ventures and in the investment banking division of Merrill Lynch. He holds a bachelor’s degree magna cum laude from Tufts University.

Kathleen DeRose is a Clinical Associate Professor of Finance at the Stern School of Business at New York University, focusing on FinTech. In addition, she is the Director of NYU’s Fubon Center for Technology, Business, and Innovation and a non-executive director of the London Stock Exchange Group and Voya Financial.

DeRose previously served as Chairman of the Board of Evolute, as Managing Director at Credit Suisse, Bessemer Trust, Scudder Stevens & Clark, and as VP at JPMorgan Chase.

Jan Hauser is an experienced board member and global finance leader. Jan serves on the Vonage board of directors and is also a member of Women Corporate Directors and the Northeast Audit Committee Network.

Previously, Hauser held senior roles at GE and PwC. She represented PwC on the FASB’s Emerging Issues Task Force and Financial Accounting Standards Advisory Council, and worked in the Office of the Chief Accountant at the SEC. She graduated from the University of Wisconsin and is a licensed CPA.

Larry Leibowitz is an experienced finance and technology entrepreneur. He serves on the Board of Directors of Cowen, Inc., an independent investment bank, and several private companies.

Leibowitz served as Chief Operating Officer, Head of Global Equities Markets and Board Director of NYSE Euronext from 2007 to 2013. He started his career at Morgan Stanley and holds a bachelor’s degree summa cum laude in Economics from Princeton University.

Roy Luo has been a member of Enfusion’s board of directors since 2021 and a member of the board of managers of Enfusion Ltd. LLC since December 2020.

Luo has also served as an investor at ICONIQ Capital since April 2018, and was previously an investor at Technology Crossover Ventures. He holds a bachelor’s degree from Yale University.

Oleg Movchan holds leadership and advisory roles at Revolution Global, Gimel Tech Ventures, Quiet Light Partners, and Kameosa Capital, LLC. He previously served in risk leadership roles at several hedge funds and asset management firms.

Movchan is a graduate of the General Management Program from the Aresty Institute of Executive Education at the Wharton School. He holds a Master of Science degree and an MBA from the University of Chicago and a master’s degree from Kharkiv State University (Ukraine).

Deirdre Somers is an experienced asset management industry executive, having spent her more than 30-year career as the former CEO of a securities exchange and as an independent non-executive director, committee member, and chairman, among other roles. Somers has both international experience and industry knowledge in financial products, market structure, and EU regulation, as well as in corporate actions and public market transitions.

Somers is currently an independent non-executive director (INED) and committee member of Aquis Exchange PLC, Blackrock iShares, Cancer Trials Ireland (Chair), Episode Inc, and Kenmare Resources plc.